Hibsago (bepirovirsen)

Chronic hepatitis B virus infection in adults without cirrhosis

Also known as GSK3228836

Manufacturer: GSK
Regulatory status: ApprovedNDA submitted in the first quarter of 2026 and approved October 2026
Launch: Anticipated before the end of 2026
Last updated: October 22, 2026

Section

Product information and disease description Place of product in therapy

Approaches to treatment

90 evidence topics · 35 sources

Current treatment options and standard of care39 evidence topics · 17 sources
Place in treatment, anticipated use, and care setting9 evidence topics · 7 sources
Heterogeneity of treatment effect9 evidence topics · 9 sources
Care management intervention strategies10 evidence topics · 10 sources
Other product development or post-marketing obligations required by the FDA6 evidence topics · 5 sources
Ongoing post-approval monitoring7 evidence topics · 3 sources
Expected outcomes of therapy10 evidence topics · 11 sources